Dr David Robert Grimes looks at the eye health issues that are making the news.
NHS to save millions on AMD treatment
A landmark ruling promises to substantially reduce the cost of treating wet age-related macular degeneration (AMD) – and has significant implications for future drug policy. Bayer and Novartis had attempted to stop clinical commissioning groups (CCGs) from prescribing Avastin – a widely used and cheaper treatment, but unlicensed for AMD.
In September, the High Court ruled against the drug giants.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
